April 2, 2024 - IGC Pharma released positive interim data from its ongoing Phase 2 CALMA trial for agitation in Alzheimer's disease, providing early validation of IGC-AD1's therapeutic promise.

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and ...

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

About IGC Pharma (dba IGC): IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with ...

IGC-AD1 is IGC Pharma's investigational cannabinoid-based therapy currently in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study (CALMA) evaluating its safety and efficacy ...

Review quarterly and annual revenue, net income, and cash flow for IGC Pharma Inc (IGC:XASE) stock through the last fiscal year.

April 2, 2024 - IGC Pharma released positive interim data from its ongoing Phase 2 CALMA trial for agitation in Alzheimer's disease, providing early validation of IGC-AD1's therapeutic promise.

POTOMAC, MARYLAND/ ACCESS Newswire/ June 30, 2025/ IGC Pharma, Inc., a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders ...